Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 21;8(8):CD016094.
doi: 10.1002/14651858.CD016094.

Immunosuppressants for IgG4-related disease

Giovanni Cagnotto  1 , Rebecka Teresia Bäcklund  1 , Anders Bengtsson  2 , Matteo Bruschettini  3 ; supported by Cochrane Sweden
Affiliations

Immunosuppressants for IgG4-related disease

Giovanni Cagnotto et al. Cochrane Database Syst Rev. .

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of immunosuppressants with or without corticosteroids compared to corticosteroid monotherapy for the treatment of IgG4-related disease in people 18 years or older.

PubMed Disclaimer

Conflict of interest statement

GC: Alfasigma S.p.A. (Grant/Contract); payment made to home institution with no financial benefits from this payment and did not have access to or control of the funds; works as Senior Consultant Rheumatologist, Skåne University Hospital Malmö, Sweden.

MB: no relevant interests; Senior Editor of Cochrane Neonatal and was not involved in the editorial process or decision‐making of this protocol.

RB: no relevant interests; works as a general physician (AT‐läkare) in Helsingborg.

AB: none known.

References

    1. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Modern Rheumatology 2012;22(1):1-14. [DOI: 10.1007/s10165-011-0508-6] - DOI - PMC - PubMed
    1. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet 2015;385(9976):1460-71. [DOI: 10.1016/S0140-6736(14)60720-0] - DOI - PubMed
    1. Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis & Rheumatology 2015;67(7):1688-99. [DOI: 10.1002/art.39132] - DOI - PubMed
    1. Stone JH, Zen Y, Deshpande V. IgG4-related disease. New England Journal of Medicine 2012;366(6):539-51. [DOI: 10.1056/NEJMra1104650] - DOI - PubMed
    1. Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nature Reviews Rheumatology 2020;16(12):702-14. [DOI: 10.1038/s41584-020-0500-7] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources